With a little help from my friends: understanding the IL-23 pathway and managing psoriasis and psoriatic arthritis

Date: Thursday 23 September 2021
Time: 13.15 – 14.30  PM CET

Faculty: 

Frank Behrens (Germany)

Menno de Rie (Netherlands) (Scientific Committee)

Andreas Pinter (Germany) (Scientific Committee)



Program

13.15 – 13.20

Welcome and introduction

Andreas Pinter (Germany)

 

13.20 – 13.35

Repainting the psoriasis picture: a fresh take on IL-23 and TRM in the skin

Menno de Rie (Netherlands)

13.35 – 13.50

From research insights to therapeutic success: targeting the IL-23 pathway in the skin

Andreas Pinter (Germany)

13.50 – 14.05

Detection and management of psoriatic arthritis: spot the signs, act fast

Frank Behrens (Germany)

14.05 – 14.25

Joint decisions: towards comprehensive management of psoriasis and psoriatic arthritis

Frank Behrens (Germany), Menno de Rie (Netherlands), Andreas Pinter (Germany)

14.25 – 14.30

Concluding remarks and meeting close

Menno de Rie (Netherlands)

Educational need

Dermatologists need to understand unmet needs in the management of psoriasis and psoriatic arthritis and how current data from recently approved or pipeline compounds can help address those needs in daily clinical practice

 

Learning objectives

  • Describe the clinical implications of the pathophysiology of psoriasis and psoriatic arthritis
  • Explain recent mechanistic and clinical data on tissue-resident memory cells and IL-23-pathway inhibition and consider the impact of these data on clinical practice
  • Understand how to navigate the evolving treatment landscape and describe the differences between available biologics

Reflect on the benefits of a multidisciplinary approach to the management of psoriasis and psoriatic arthritis for optimal long-term patient outcome